Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 abnormalities in B-cell prolymphocytic leukemia

D Lens1, P J De Schouwer, R A Hamoudi

  • 1Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK.

Blood
|March 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.

Nature genetics·1997
Same author

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia.

Leukemia·1997
Same author

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.

British journal of haematology·1997
Same author

G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia.

Bone marrow transplantation·1997
Same author

Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?

Leukemia·1997
Same author

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997

p53 gene abnormalities are frequent in B-cell prolymphocytic leukemia (B-PLL), with mutations occurring in 53% of cases. These distinct p53 mutations may drive therapy resistance in B-PLL.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • B-cell prolymphocytic leukemia (B-PLL) is an aggressive mature B-cell neoplasm.
  • The role of p53 gene abnormalities in B-PLL pathogenesis and therapy resistance is not fully understood.
  • Previous studies suggest p53 alterations in various B-cell malignancies.

Purpose of the Study:

  • To investigate the incidence and patterns of p53 gene abnormalities in B-PLL.
  • To correlate p53 alterations with clinical features and treatment outcomes.
  • To compare p53 mutation patterns in B-PLL with those in other B-cell malignancies.

Main Methods:

  • Analysis of 19 B-PLL cases.
  • DNA blot for loss of heterozygosity (LOH) at 17p13.3.
  • Immunocytochemistry for p53 protein expression.

Related Experiment Videos

  • Direct DNA sequencing of p53 gene exons 5-9.

    • Main Results:

    • p53 mutations detected in 53% (10/19) of B-PLL cases.
    • LOH at 17p13.3 detected in 53% (10/19) of cases.
    • p53 expression detected in 47% (8/17) of cases.
    • Overall p53 abnormalities found in 75% (14/19) of cases.
    • Distinct p53 mutation patterns observed compared to CLL and other hematologic malignancies.
    • No correlation between p53 protein expression and mutation status.

    Conclusions:

    • p53 gene abnormalities are highly frequent in B-PLL, with a high rate of mutation.
    • The observed p53 mutations and overall abnormalities may contribute to B-PLL's aggressive nature and therapy resistance.
    • Distinct p53 mutation patterns suggest unique pathogenic mechanisms in B-PLL.